Bangwei Chen
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Bangwei Chen has a total of 62 co-authors. Here are the top co-authors by number of shared publications:
- Ying Shan
Clinical Research Academy, Peking University Shenzhen Hospital, Peking University
2 shared publications - Yueqi Lu
Department of Genetics, University of Georgia, Athens, Georgia, 30602, USA
2 shared publications Bin Li
BGI-Shenzhen, Shenzhen 518083, China
1 shared publicationBingbing Fan
Shenzhen Second People's Hospital, First Affiliated Hospital of Shenzhen University, Shenzhen 518035, Guangdong Province, China
1 shared publicationChan Kong
1 shared publicationChenxin Deng
1 shared publication
Latest Publications
- Open Access
- 26 February 2026
- Published by Elsevier in SSRN Electronic Journal
Low-Dose Terazosin for Arterial Stiffness Trial (LAST): A Randomized Controlled Trial of Structural Vascular Improvement Independent of Blood Pressure
Background: Arterial stiffness, a hallmark of vascular aging, is a prevalent and independent predictor of cardiovascular events. Current management indirectly targets hemodynamic factors but lacks therapies that directly reverse the pathological structural remodeling of the arterial wall. Preclinical evidence suggests the α1-blocker terazosin may improve vascular structure via non-hemodynamic mechanisms. We aimed to evaluate the efficacy and safety of low-dose terazosin for reducing arterial stiffness in adults.Methods: The Low-dose Terazosin for Arterial Stiffness Trial (LAST) was a randomized, parallel-group, double-blind, placebo-controlled trial conducted at a standardized vascular management center in China. Adults aged 40-70 years with elevated brachial-ankle pulse wave velocity (baPWV ≥1400 cm/s) were enrolled. Participants were randomly assigned (1:1), stratified by hypertension status, to receive terazosin 0∙5 mg daily or matching placebo for 6 months. The primary efficacy endpoint was the proportion of patients achieving a reduction in baPWV of ≥10 cm/s at 6 months, a threshold selected to distinguish a true treatment effect from measurement variability. Safety outcomes included adverse events and laboratory abnormalities. A key mechanistic outcome was the change in structural PWV, derived via biomechanical modeling to isolate intrinsic wall properties. This clinical metric was further linked to direct structural evidence through parallel histopathological examinations in an animal model. The trial is registered with ChiCTR2300076294.Findings: Between December 2023 and June 2024, 138 participants were randomized (69 per group). In the full analysis set (n=105), terazosin significantly increased the responder rate versus placebo (75∙5% [40/53] vs 55∙8% [29/52]; p=0∙041). Treatment effect was consistent across subgroups including age and hypertension status. Critically, blood pressure changes were minimal and non-significant. Structural PWV decreased markedly in the terazosin group (mean change –70∙5 cm/s, p=0∙002), indicating direct improvement in wall integrity. Safety profiles were similar between groups, with no major adverse cardiovascular events or typical α-blocker side effects observed. Parallel studies in spontaneously hypertensive rats confirmed that terazosin reduced PWV without lowering blood pressure and preserved aortic elastic fiber integrity.Interpretation: Low-dose terazosin improves arterial stiffness through a direct, blood pressure-independent effect on vascular wall structure. This proof-of-concept study provides the novel clinical evidence for a targeted, non-hemodynamic pharmacological strategy against arterial stiffening, addressing a fundamental gap in the management of vascular aging.
- 26 February 2026
- Published by Elsevier in SSRN Electronic Journal
Open AccessLow-Dose Terazosin for Arterial Stiffness Trial (LAST): A Randomized Controlled Trial of Structural Vascular Improvement Independent of Blood Pressure
Background: Arterial stiffness, a hallmark of vascular aging, is a prevalent and independent predictor of cardiovascular events. Current management indirectly targets hemodynamic factors but lacks therapies that directly reverse the pathological structural remodeling of the arterial wall. Preclinical evidence suggests the α1-blocker terazosin may improve vascular structure via non-hemodynamic mechanisms. We aimed to evaluate the efficacy and safety of low-dose terazosin for reducing arterial stiffness in adults.Methods: The Low-dose Terazosin for Arterial Stiffness Trial (LAST) was a randomized, parallel-group, double-blind, placebo-controlled trial conducted at a standardized vascular management center in China. Adults aged 40-70 years with elevated brachial-ankle pulse wave velocity (baPWV ≥1400 cm/s) were enrolled. Participants were randomly assigned (1:1), stratified by hypertension status, to receive terazosin 0∙5 mg daily or matching placebo for 6 months. The primary efficacy endpoint was the proportion of patients achieving a reduction in baPWV of ≥10 cm/s at 6 months, a threshold selected to distinguish a true treatment effect from measurement variability. Safety outcomes included adverse events and laboratory abnormalities. A key mechanistic outcome was the change in structural PWV, derived via biomechanical modeling to isolate intrinsic wall properties. This clinical metric was further linked to direct structural evidence through parallel histopathological examinations in an animal model. The trial is registered with ChiCTR2300076294.Findings: Between December 2023 and June 2024, 138 participants were randomized (69 per group). In the full analysis set (n=105), terazosin significantly increased the responder rate versus placebo (75∙5% [40/53] vs 55∙8% [29/52]; p=0∙041). Treatment effect was consistent across subgroups including age and hypertension status. Critically, blood pressure changes were minimal and non-significant. Structural PWV decreased markedly in the terazosin group (mean change –70∙5 cm/s, p=0∙002), indicating direct improvement in wall integrity. Safety profiles were similar between groups, with no major adverse cardiovascular events or typical α-blocker side effects observed. Parallel studies in spontaneously hypertensive rats confirmed that terazosin reduced PWV without lowering blood pressure and preserved aortic elastic fiber integrity.Interpretation: Low-dose terazosin improves arterial stiffness through a direct, blood pressure-independent effect on vascular wall structure. This proof-of-concept study provides the novel clinical evidence for a targeted, non-hemodynamic pharmacological strategy against arterial stiffening, addressing a fundamental gap in the management of vascular aging.
- Open Access
- 16 February 2023
- Published by Elsevier in Clinical Nutrition
- Vol. 42 (4) , 511-518
Sex-specific equations to estimate body composition: Derivation and validation of diagnostic prediction models using UK Biobank
- 16 February 2023
- Published by Elsevier in Clinical Nutrition
- Vol. 42 (4) , 511-518
Open AccessSex-specific equations to estimate body composition: Derivation and validation of diagnostic prediction models using UK Biobank
- Open Access
- 15 March 2022
- Published by International Scientific Information, Inc. in Medical Science Monitor
- Vol. 28, e935340-1-e935340-9
Association Between Thromboelastography and Coronary Heart Disease
Thromboelastography (TEG) is a novel blood viscoelasticity detection method revealing blood coagulation status and has been reported to be helpful in predicting clinical outcomes in patients with cardiovascular diseases (CVD). In this study, we aimed to investigate the association between TEG and CVD. A single-center case-control study was performed. Individuals who took TEG tests at Tongji Hospital in Wuhan, China from 2015 to 2019 were included. The nearest-neighbor Mahalanobis matching with replacement, within propensity score calipers of 0.25 was used to control the covariate imbalance between CVD patients and controls. Logistic regression analyses were conducted to assess the relationship between TEG and CVD. Subgroup and sensitivity analyses were performed to evaluate the robustness of the association between TEG and CVD. After matching, a total of 151 participants were included in this study, with 83 patients having CVD (49 patients having coronary heart disease [CHD] and 34 patients having an ischemic stroke). By comparison, CHD patients had a significantly higher maximum amplitude (MA) (P=0.02) than controls. After multivariable adjustment, MA (OR 1.11, 95% CI 1.01–1.24, P=0.04) was independently associated with CHD. The association between MA and CHD remained robust across subgroups and in sensitivity analyses. The current study suggests that MA is significantly associated with CHD. Enhanced platelet reactivity as described by high MA might be associated with risk of CHD. The exact role of MA in the measurement of CHD risk needs to be further examined in large-scale prospective cohort studies.
- 15 March 2022
- Published by International Scientific Information, Inc. in Medical Science Monitor
- Vol. 28, e935340-1-e935340-9
Open AccessAssociation Between Thromboelastography and Coronary Heart Disease
Thromboelastography (TEG) is a novel blood viscoelasticity detection method revealing blood coagulation status and has been reported to be helpful in predicting clinical outcomes in patients with cardiovascular diseases (CVD). In this study, we aimed to investigate the association between TEG and CVD. A single-center case-control study was performed. Individuals who took TEG tests at Tongji Hospital in Wuhan, China from 2015 to 2019 were included. The nearest-neighbor Mahalanobis matching with replacement, within propensity score calipers of 0.25 was used to control the covariate imbalance between CVD patients and controls. Logistic regression analyses were conducted to assess the relationship between TEG and CVD. Subgroup and sensitivity analyses were performed to evaluate the robustness of the association between TEG and CVD. After matching, a total of 151 participants were included in this study, with 83 patients having CVD (49 patients having coronary heart disease [CHD] and 34 patients having an ischemic stroke). By comparison, CHD patients had a significantly higher maximum amplitude (MA) (P=0.02) than controls. After multivariable adjustment, MA (OR 1.11, 95% CI 1.01–1.24, P=0.04) was independently associated with CHD. The association between MA and CHD remained robust across subgroups and in sensitivity analyses. The current study suggests that MA is significantly associated with CHD. Enhanced platelet reactivity as described by high MA might be associated with risk of CHD. The exact role of MA in the measurement of CHD risk needs to be further examined in large-scale prospective cohort studies.
- Open Access
- 1 May 2019
- Published by Oxford University Press (OUP) in GigaScience
- Vol. 8 (5)
Single-cell transcriptomic landscape of nucleated cells in umbilical cord blood
Background: For both pediatric and adult patients, umbilical cord blood (UCB) transplant is a therapeutic option for a variety of hematologic diseases, such as blood cancers, myeloproliferative disorders, genetic diseases, and metabolic disorders. However, the level of cellular heterogeneity and diversity of nucleated cells in UCB has not yet been assessed in an unbiased and systemic fashion. In the present study, nucleated cells from UCB were subjected to single-cell RNA sequencing to simultaneously profile the gene expression signatures of thousands of cells, generating a rich resource for further functional studies. Here, we report the transcriptomes of 17,637 UCB cells, covering 12 major cell types, many of which can be further divided into distinct subpopulations. Results: Pseudotemporal ordering of nucleated red blood cells identifies wave-like activation and suppression of transcription regulators, leading to a polarized cellular state, which may reflect nucleated red blood cell maturation. Progenitor cells in UCB also comprise 2 subpopulations with activation of divergent transcription programs, leading to specific cell fate commitment. Detailed profiling of cytotoxic cell populations unveiled granzymes B and K signatures in natural killer and natural killer T-cell types in UCB. Conclusions: Taken together, our data form a comprehensive single-cell transcriptomic landscape that reveals previously unrecognized cell types, pathways, and mechanisms of gene expression regulation. These data may contribute to the efficacy and outcome of UCB transplant, broadening the scope of research and clinical innovations.
- 1 May 2019
- Published by Oxford University Press (OUP) in GigaScience
- Vol. 8 (5)
Open AccessSingle-cell transcriptomic landscape of nucleated cells in umbilical cord blood
Background: For both pediatric and adult patients, umbilical cord blood (UCB) transplant is a therapeutic option for a variety of hematologic diseases, such as blood cancers, myeloproliferative disorders, genetic diseases, and metabolic disorders. However, the level of cellular heterogeneity and diversity of nucleated cells in UCB has not yet been assessed in an unbiased and systemic fashion. In the present study, nucleated cells from UCB were subjected to single-cell RNA sequencing to simultaneously profile the gene expression signatures of thousands of cells, generating a rich resource for further functional studies. Here, we report the transcriptomes of 17,637 UCB cells, covering 12 major cell types, many of which can be further divided into distinct subpopulations. Results: Pseudotemporal ordering of nucleated red blood cells identifies wave-like activation and suppression of transcription regulators, leading to a polarized cellular state, which may reflect nucleated red blood cell maturation. Progenitor cells in UCB also comprise 2 subpopulations with activation of divergent transcription programs, leading to specific cell fate commitment. Detailed profiling of cytotoxic cell populations unveiled granzymes B and K signatures in natural killer and natural killer T-cell types in UCB. Conclusions: Taken together, our data form a comprehensive single-cell transcriptomic landscape that reveals previously unrecognized cell types, pathways, and mechanisms of gene expression regulation. These data may contribute to the efficacy and outcome of UCB transplant, broadening the scope of research and clinical innovations.
- Open Access
- 7 March 2019
- Published by Frontiers Media SA in Frontiers in Genetics
- Vol. 10, 152
Evolution and Comprehensive Analysis of DNaseI Hypersensitive Sites in Regulatory Regions of Primate Brain-Related Genes
How the human brain differs from those of non-human primates is largely unknown and the complex drivers underlying such differences at the genomic level remain unclear. In this study, we selected 243 brain-related genes, based on Gene Ontology, and identified 184,113 DNaseI hypersensitive sites (DHSs) within their regulatory regions. To performed comprehensive evolutionary analyses, we set strict filtering criteria for alignment quality and filtered 39,132 DHSs for inclusion in the investigation and found that 2,397 (~6%) exhibited evidence of accelerated evolution (aceDHSs), which was a much higher proportion that DHSs genome-wide. Target genes predicted to be regulated by brain-aceDHSs were functionally enriched for brain development and exhibited differential expression between human and chimpanzee. Alignments indicated 61 potential human-specific transcription factor binding sites in brain-aceDHSs, including for CTCF, FOXH1, and FOXQ1. Furthermore, based on GWAS, Hi-C, and eQTL data, 16 GWAS SNPs, and 82 eQTL SNPs were in brain-aceDHSs that regulate genes related to brain development or disease. Among these brain-aceDHSs, we confirmed that one enhanced the expression of GPR133, using CRISPR-Cas9 and western blotting. The GPR133 gene is associated with glioblastoma, indicating that SNPs within DHSs could be related to brain disorders. These findings suggest that brain-related gene regulatory regions are under adaptive evolution and contribute to the differential expression profiles among primates, providing new insights into the genetic basis of brain phenotypes or disorders between humans and other primates.
- 7 March 2019
- Published by Frontiers Media SA in Frontiers in Genetics
- Vol. 10, 152
Open AccessEvolution and Comprehensive Analysis of DNaseI Hypersensitive Sites in Regulatory Regions of Primate Brain-Related Genes
How the human brain differs from those of non-human primates is largely unknown and the complex drivers underlying such differences at the genomic level remain unclear. In this study, we selected 243 brain-related genes, based on Gene Ontology, and identified 184,113 DNaseI hypersensitive sites (DHSs) within their regulatory regions. To performed comprehensive evolutionary analyses, we set strict filtering criteria for alignment quality and filtered 39,132 DHSs for inclusion in the investigation and found that 2,397 (~6%) exhibited evidence of accelerated evolution (aceDHSs), which was a much higher proportion that DHSs genome-wide. Target genes predicted to be regulated by brain-aceDHSs were functionally enriched for brain development and exhibited differential expression between human and chimpanzee. Alignments indicated 61 potential human-specific transcription factor binding sites in brain-aceDHSs, including for CTCF, FOXH1, and FOXQ1. Furthermore, based on GWAS, Hi-C, and eQTL data, 16 GWAS SNPs, and 82 eQTL SNPs were in brain-aceDHSs that regulate genes related to brain development or disease. Among these brain-aceDHSs, we confirmed that one enhanced the expression of GPR133, using CRISPR-Cas9 and western blotting. The GPR133 gene is associated with glioblastoma, indicating that SNPs within DHSs could be related to brain disorders. These findings suggest that brain-related gene regulatory regions are under adaptive evolution and contribute to the differential expression profiles among primates, providing new insights into the genetic basis of brain phenotypes or disorders between humans and other primates.